Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
- 1 April 2017
- journal article
- research article
- Published by Elsevier in The Lancet Haematology
- Vol. 4 (4) , e176-e182
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute of the National Institutes of Health (award numbers U10CA180821 and U10CA180882)
This publication has 24 references indexed in Scilit:
- Idelalisib-associated ColitisAmerican Journal of Surgical Pathology, 2015
- Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell LymphomaNew England Journal of Medicine, 2015
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialThe Lancet Oncology, 2014
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancerNature, 2014
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2014
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent LymphomaNew England Journal of Medicine, 2014
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging TherapiesThe Cancer Journal, 2014
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialThe Lancet Oncology, 2012
- Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessAnnals of Oncology, 2012
- A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphomaAnnals of Oncology, 2007